Rates of drug-related nonhematologic adverse events that occurred in ≥10% of patients
| . | Treated patients, % . | |||
|---|---|---|---|---|
| . | Dasatinib, n = 258 . | Imatinib, n = 258 . | ||
| . | All grades . | Grade 3/4 . | All grades . | Grade 3/4 . |
| Fluid retention | 31 | 3 | 44 | <1 |
| Superficial edema | 13 | 0 | 37 | <1 |
| Pleural effusion | 19 | 2 | <1 | 0 |
| Myalgia* | 23 | 0 | 41 | <1 |
| Nausea | 10 | 0 | 24 | 0 |
| Diarrhea | 21 | <1 | 22 | 1 |
| Vomiting | 5 | 0 | 11 | 0 |
| Rash | 13 | 0 | 18 | 2 |
| Headache | 13 | 0 | 11 | 0 |
| Fatigue | 9 | <1 | 11 | 0 |
| . | Treated patients, % . | |||
|---|---|---|---|---|
| . | Dasatinib, n = 258 . | Imatinib, n = 258 . | ||
| . | All grades . | Grade 3/4 . | All grades . | Grade 3/4 . |
| Fluid retention | 31 | 3 | 44 | <1 |
| Superficial edema | 13 | 0 | 37 | <1 |
| Pleural effusion | 19 | 2 | <1 | 0 |
| Myalgia* | 23 | 0 | 41 | <1 |
| Nausea | 10 | 0 | 24 | 0 |
| Diarrhea | 21 | <1 | 22 | 1 |
| Vomiting | 5 | 0 | 11 | 0 |
| Rash | 13 | 0 | 18 | 2 |
| Headache | 13 | 0 | 11 | 0 |
| Fatigue | 9 | <1 | 11 | 0 |
Includes myalgia, muscle spasms, and musculoskeletal pain.